Introduction: luteinizing hormone for life's journey
- PMID: 40247364
- PMCID: PMC12004544
- DOI: 10.1186/s12958-025-01357-4
Introduction: luteinizing hormone for life's journey
Conflict of interest statement
Declarations. Ethics approval and consent to participate: Not applicable. Consent for publication: Not applicable. Competing interests: CA, SCE, and PH declare receipt of unrestricted research grants from Merck; and lecture fees from Merck, MedEA, and Event Planet. RF has received lecture fees from Merck, MedEA, and Event Planet.
References
-
- POSEIDON Group (Patient-Oriented Strategies Encompassing IndividualizeD Oocyte Number); Alviggi C, Andersen CY, Buehler K, Conforti A, De Placido G, et al. A new more detailed stratification of low responders to ovarian stimulation: from a poor ovarian response to a low prognosis concept. Fertil Steril. 2016;105:1452–3. - PubMed
-
- Conforti A, Esteves SC, Humaidan P, Longobardi S, D’Hooghe T, Orvieto R, et al. Recombinant human luteinizing hormone co-treatment in ovarian stimulation for assisted reproductive technology in women of advanced reproductive age: a systematic review and meta-analysis of randomized controlled trials. Reprod Biol Endocrinol. 2021;19:91. - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources